Christopher D. King - Concepedia

Author

Christopher D. King

Cincinnati Children's Hospital Medical Center ORCID

Also Known As

C D King, C King, C. D. King, C. King, C.D King, C.D. King, Chris D King, Christopher D King, Christopher D. King, Christopher King

173

Publications

9.6K

Citations

H-Index

134

Concepts

All Affiliations

Cincinnati Children's Hospital Medical Center University of Cincinnati Medical Center University of Florida University of Alabama at Birmingham University of Iowa

About

Christopher D. King is an author at Cincinnati Children's Hospital Medical Center specializing in medicine, pharmacology, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	37	3.6K
2	Health Sciences	14	17	2.1K
3	Natural Sciences	6	6	907
4	Social Sciences	5	5	356
5	Engineering	1	1	158

Christopher D. King

Publications

6.2K

Citations

H-Index

Page 1

	Year	Citations
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. Lalitha Iyer, Christopher D. King, P. F. Whitington, Journal of Clinical Investigation Aldo-keto ReductaseChemoprevention StrategyGeneticsMolecular BiologyPathology	1998	677
Human UGT2B7 catalyzes morphine glucuronidation. Birgit L. Coffman, Gladys R. Rios, Christopher D. King, PubMed Molecular PharmacologyMedicinal ChemistryBiochemistryG Protein-coupled ReceptorMedicine	1997	426
The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Birgit L. Coffman, Christopher D. King, Gladys R. Rios, PubMed Other XenobioticsHk 293PharmacotherapyGlucocorticoidExperimental Pharmacology	1998	326
Deficiency in endogenous modulation of prolonged heat pain in patients with Irritable Bowel Syndrome and Temporomandibular Disorder Christopher D. King, Fong Wong, T. Currie, Pain Pain DisordersPain MedicineNeuropathic PainThermal TherapyChronic Pain Patients	2009	285
Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Mitchell D. Green, Christopher D. King, B. Mojarrabi, PubMed Bioorganic ChemistryAldo-keto ReductaseOther XenobioticsTertiary Amine MoietyGlycobiology	1998	258
Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma Flavia V. Castelino, Jon Seiders, Gretchen Bain, Arthritis & Rheumatism	2011	168
Expression of UDP-Glucuronosyltransferases (UGTs) 2B7 and 1A6 in the Human Brain and Identification of 5-Hydroxytryptamine as a Substrate Christopher D. King, Gladys R. Rios, J.A. Assouline, Archives of Biochemistry and Biophysics Neurodegenerative DiseasesMolecular NeuroscienceNeurochemical BiomarkersNeurologyNeuroscience	1999	163
The Glucuronidation of Exogenous and Endogenous Compounds by Stably Expressed Rat and Human UDP-Glucuronosyltransferase 1.1 Christopher D. King, Mitchell D. Green, Gladys R. Rios, Archives of Biochemistry and Biophysics BiosynthesisEngineeringBiochemistryGlycobiologyEndogenous Compounds	1996	158
Characterization of Rat and Human UDP-Glucuronosyltransferases Responsible for the in Vitro Glucuronidation of Diclofenac Christopher D. King Toxicological Sciences Enzyme KineticsBiochemistryVitro GlucuronidationRat Ugt2b1Medicine	2001	154
Synthesis, characterization, and first successful monkey imaging studies of metabotropic glutamate receptor subtype 5 (mGluR5) PET radiotracers Terence G. Hamill, Stephen M. Krause, Christine Ryan, Synapse	2005	152

Page 1